Thermo Fisher Scientific Phospho-ABL1/ABL2 (Tyr393, Tyr439) Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1:500-1:1,000

-

Immunohistochemistry (Paraffin) (IHC (P))

1:50-1:100

-

Immunocytochemistry (ICC/IF)

1:100-1:200

-

Product Specifications

Species Reactivity

Human, Mouse

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Peptide sequence around phosphorylation site of tyrosine 393/439 (D-T-Y(p)-T-A) derived from Human ABL1/2. if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:ABL1/ABL2,uniProtId:P00519-1,ncbiNodeId:9606,antigenRange:391-395|437-441,antigenLength:1130,antigenImageFileName:PA5-37468_ABL1ABL2_P00519-1_Rabbit.svg,antigenImageFileNamePDP:PA5-37468_ABL1ABL2_P00519-1_Rabbit_PDP.jpeg,sortOrder:1},{targetFamily:ABL1/ABL2,uniProtId:P42684-1,ncbiNodeId:9606,antigenRange:391-395|437-441,antigenLength:1182,antigenImageFileName:PA5-37468_ABL1ABL2_P42684-1_Rabbit.svg,antigenImageFileNamePDP:PA5-37468_ABL1ABL2_P42684-1_Rabbit_PDP.jpeg,sortOrder:2}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.4, with 50% glycerol

Contains

0.02% sodium azide

Storage conditions

-20°C

Shipping conditions

Wet ice

RRID

AB_2554077

Product Specific Information

A suggested positive control for Western blot is HL60 cells; suggested positive control for IHC is human breast carcinoma; suggested positive control for ICC/IF is Hela cells.

Target Information

The Abl oncogene was initially identified as the viral transforming gene of Abelson murine leukemia virus (A-MuLV). The major translational product of c-Abl has been identified as a protein with tyrosine kinase activity and an SH2 domain. The Abl oncogene is implicated in several human leukemias including 90-95% of chronic myelocytic leukemia (CML), 20-25% of adult acute lymphoblastic leukemia (ALL) and 2-5% of pediatric ALL. In these leukemias the c-Abl proto-oncogene undergoes a (9;22) chromosomal translocation producing the Philadelphia (Ph1) chromosome. The molecular consequence of this translocation is the generation of a chimeric Bcr/c-Abl mRNA encoding activated Abl protein-tyrosine kinase.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.